MA37524B1 - Procedes de production de chlorhydrate d'anamoreline presentant une teneur en chlorure regulee - Google Patents
Procedes de production de chlorhydrate d'anamoreline presentant une teneur en chlorure reguleeInfo
- Publication number
- MA37524B1 MA37524B1 MA37524A MA37524A MA37524B1 MA 37524 B1 MA37524 B1 MA 37524B1 MA 37524 A MA37524 A MA 37524A MA 37524 A MA37524 A MA 37524A MA 37524 B1 MA37524 B1 MA 37524B1
- Authority
- MA
- Morocco
- Prior art keywords
- chloride content
- anamoreline
- hydrochloride
- producing
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
La présente invention concerne des formes particulaires de monochlorhydrate d'anamoréline, ou une composition contenant du monochlorhydrate d'anamoréline présentant une teneur en chlorure régulée, de préférence isolé sous une forme particulaire fine et/ou amorphe, des procédés de préparation des formes particulaires, ainsi que des compositions pharmaceutiques contenant les formes particulaires.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261636108P | 2012-04-20 | 2012-04-20 | |
PCT/US2013/037159 WO2013158874A1 (fr) | 2012-04-20 | 2013-04-18 | Procédés de production de chlorhydrate d'anamoréline présentant une teneur en chlorure régulée |
Publications (2)
Publication Number | Publication Date |
---|---|
MA37524A1 MA37524A1 (fr) | 2016-06-30 |
MA37524B1 true MA37524B1 (fr) | 2017-04-28 |
Family
ID=48225135
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA37524A MA37524B1 (fr) | 2012-04-20 | 2013-04-18 | Procedes de production de chlorhydrate d'anamoreline presentant une teneur en chlorure regulee |
Country Status (47)
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3353B1 (ar) | 2012-04-20 | 2019-03-13 | Ono Pharmaceutical Co | شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي |
AP2017009772A0 (en) * | 2014-09-04 | 2017-02-28 | Helsinn Healthcare Sa | Medical treatments based on anamorelin |
MA43294A1 (fr) | 2015-07-24 | 2020-04-30 | Newlink Genetics Corp | Sels et promédicaments de 1-méthyl -d-tryptophane |
CN108239141A (zh) * | 2016-12-23 | 2018-07-03 | 江苏先声药业有限公司 | 一种阿拉莫林的制备方法 |
US20220323430A1 (en) * | 2019-08-30 | 2022-10-13 | Helsinn Healthcare Sa | Methods of manufacturing anamorelin tablets having improved stability |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA73530C2 (uk) * | 1999-11-10 | 2005-08-15 | Ново Нордіск А/С | Сполука з властивостями вивільнювати гормон росту |
CN1882526A (zh) * | 2003-09-26 | 2006-12-20 | 兰贝克赛实验室有限公司 | 制备伏格列波糖的方法 |
EP1768976B1 (fr) | 2004-06-29 | 2017-04-26 | Helsinn Healthcare S.A. | Formes cristallines d'acide (3r)-1-(2-methylalanyl-d-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylique 1,2,2-trimethylhydrazide |
WO2008100448A2 (fr) | 2007-02-13 | 2008-08-21 | Helsinn Therapeutics (U.S.), Inc. | Procédé de traitement des troubles prolifératifs cellulaires utilisant un sécrétagogue d'hormone de croissance |
UA105657C2 (uk) | 2009-02-27 | 2014-06-10 | Хелсінн Терапьютікс (Ю.Ес.), Інк. | Поліпшені способи лікування мігрені на основі анамореліну |
JO3353B1 (ar) | 2012-04-20 | 2019-03-13 | Ono Pharmaceutical Co | شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي |
-
2013
- 2013-04-15 JO JOP/2013/0101A patent/JO3353B1/ar active
- 2013-04-17 AR ARP130101264A patent/AR090725A1/es not_active Application Discontinuation
- 2013-04-18 US US13/865,649 patent/US20140018391A1/en not_active Abandoned
- 2013-04-18 BR BR112014025972A patent/BR112014025972A8/pt not_active Application Discontinuation
- 2013-04-18 AU AU2013249197A patent/AU2013249197B2/en active Active
- 2013-04-18 SI SI201330963T patent/SI2838892T1/en unknown
- 2013-04-18 KR KR1020197011485A patent/KR102141323B1/ko active IP Right Grant
- 2013-04-18 UA UAA201412382A patent/UA116207C2/uk unknown
- 2013-04-18 SG SG10201608488RA patent/SG10201608488RA/en unknown
- 2013-04-18 PT PT137193447T patent/PT2838892T/pt unknown
- 2013-04-18 CA CA2869893A patent/CA2869893C/fr active Active
- 2013-04-18 AP AP2014008013A patent/AP2014008013A0/xx unknown
- 2013-04-18 EP EP17192651.2A patent/EP3290410B1/fr active Active
- 2013-04-18 JP JP2015507175A patent/JP6109925B2/ja active Active
- 2013-04-18 HU HUE13719344A patent/HUE035697T2/en unknown
- 2013-04-18 TW TW102113767A patent/TWI589572B/zh active
- 2013-04-18 CN CN201380003026.5A patent/CN103857669B/zh active Active
- 2013-04-18 KR KR1020147018116A patent/KR101972998B1/ko active IP Right Grant
- 2013-04-18 CN CN201910323606.1A patent/CN110041398A/zh active Pending
- 2013-04-18 GE GEAP201313634A patent/GEP20186902B/en unknown
- 2013-04-18 PL PL17192651T patent/PL3290410T3/pl unknown
- 2013-04-18 PE PE2014001624A patent/PE20150084A1/es not_active Application Discontinuation
- 2013-04-18 TW TW106105466A patent/TWI677494B/zh active
- 2013-04-18 EP EP13719344.7A patent/EP2838892B1/fr active Active
- 2013-04-18 DK DK19155007.8T patent/DK3517532T3/da active
- 2013-04-18 MY MYPI2014703092A patent/MY170068A/en unknown
- 2013-04-18 HU HUE17192651A patent/HUE050865T2/hu unknown
- 2013-04-18 SG SG11201406478XA patent/SG11201406478XA/en unknown
- 2013-04-18 MD MDA20140122A patent/MD4615C1/ro active IP Right Grant
- 2013-04-18 MX MX2014012178A patent/MX354793B/es active IP Right Grant
- 2013-04-18 CN CN201910323598.0A patent/CN110041304A/zh active Pending
- 2013-04-18 EA EA201401151A patent/EA031581B1/ru unknown
- 2013-04-18 DK DK13719344.7T patent/DK2838892T3/en active
- 2013-04-18 PT PT191550078T patent/PT3517532T/pt unknown
- 2013-04-18 RS RS20180192A patent/RS56869B1/sr unknown
- 2013-04-18 MA MA37524A patent/MA37524B1/fr unknown
- 2013-04-18 EP EP19155007.8A patent/EP3517532B1/fr active Active
- 2013-04-18 CA CA3031652A patent/CA3031652C/fr active Active
- 2013-04-18 ES ES17192651T patent/ES2820354T3/es active Active
- 2013-04-18 PL PL13719344T patent/PL2838892T3/pl unknown
- 2013-04-18 WO PCT/US2013/037159 patent/WO2013158874A1/fr active Application Filing
- 2013-04-18 ES ES13719344.7T patent/ES2658862T3/es active Active
- 2013-04-18 NZ NZ700833A patent/NZ700833A/en unknown
- 2013-04-18 ME MEP-2018-47A patent/ME02966B/fr unknown
- 2013-04-18 LT LTEP13719344.7T patent/LT2838892T/lt unknown
- 2013-04-18 SI SI201331789T patent/SI3290410T1/sl unknown
- 2013-04-19 UY UY0001034753A patent/UY34753A/es active IP Right Grant
- 2013-07-29 NO NO13823572A patent/NO2877697T3/no unknown
-
2014
- 2014-10-07 IL IL235064A patent/IL235064B/en active IP Right Grant
- 2014-10-08 TN TN2014000421A patent/TN2014000421A1/fr unknown
- 2014-10-20 PH PH12014502351A patent/PH12014502351A1/en unknown
- 2014-10-20 DO DO2014000235A patent/DOP2014000235A/es unknown
- 2014-10-20 CL CL2014002817A patent/CL2014002817A1/es unknown
- 2014-10-20 NI NI201400124A patent/NI201400124A/es unknown
- 2014-11-12 US US14/539,318 patent/US9403867B2/en active Active
- 2014-11-18 EC ECIEPI201427739A patent/ECSP14027739A/es unknown
- 2014-11-19 CR CR20140530A patent/CR20140530A/es unknown
- 2014-11-19 ZA ZA2014/08508A patent/ZA201408508B/en unknown
- 2014-11-20 CO CO14255094A patent/CO7131356A2/es unknown
-
2015
- 2015-04-02 HK HK15103359.2A patent/HK1202863A1/xx unknown
-
2016
- 2016-04-21 US US15/135,107 patent/US9956261B2/en active Active
- 2016-04-21 US US15/135,147 patent/US9872883B2/en active Active
- 2016-04-21 US US15/135,051 patent/US9981002B2/en active Active
-
2017
- 2017-03-08 JP JP2017043785A patent/JP6284665B2/ja active Active
-
2018
- 2018-01-30 JP JP2018013782A patent/JP6616853B2/ja active Active
- 2018-02-21 HR HRP20180316TT patent/HRP20180316T1/hr unknown
- 2018-03-05 CY CY20181100270T patent/CY1120276T1/el unknown
- 2018-04-26 US US15/963,284 patent/US10300105B2/en active Active
- 2018-06-28 HK HK18108293.7A patent/HK1248694A1/zh unknown
-
2019
- 2019-04-14 US US16/383,623 patent/US10576122B2/en active Active
-
2020
- 2020-01-24 US US16/751,836 patent/US10905737B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GEP20156366B (en) | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use | |
NZ716487A (en) | Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide | |
MA35567B1 (fr) | Nouvelle formulation de méloxicam | |
MX2012007273A (es) | Pteridinonas como inhibidores de la quinasa tipo polo. | |
MX338338B (es) | Composiciones y metodos utiles para el tratamiento de enfermedades respiratorias. | |
TW200619220A (en) | New hydrates and polymorphs of 4-[[(7r)-8-cyclopentyl-7-ethyl-5, 6, 7, 8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-mithoxy-n-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament | |
MA33295B1 (fr) | Nouvelle formulation de diclofénac | |
MX2009008253A (es) | Derivados de 2-aminopiridina utiles como inhibidores de cinasa. | |
AU2012258977A8 (en) | Inhibitors of LRRK2 kinase activity | |
EA200702329A1 (ru) | Замещенные пирролпиридины, содержащие их композиции, способ получения и применение | |
EA200901138A1 (ru) | Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение | |
EA201100138A1 (ru) | 4-феноксиметилпиперидины в качестве модуляторов активности gpr119 | |
MX2009009592A (es) | Aminopiridinas utiles como inhibidores de proteinas cinasas. | |
MX2009006345A (es) | Compuestos utiles como inhibidores de proteina cinasa. | |
MA30694B1 (fr) | Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique. | |
MA33296B1 (fr) | Nouvelle formulation d'indométhacine | |
EA200801184A1 (ru) | Производные пипередин-4-ил-пиридазин-3-иламина как быстро диссоциирующие антагонисты рецептора дофамина 2 | |
MY179527A (en) | Catecholamine derivatives useful for the treatment of parkinson's disease | |
GB2511685A (en) | Muscarinic m1 receptor agonists | |
MA37524B1 (fr) | Procedes de production de chlorhydrate d'anamoreline presentant une teneur en chlorure regulee | |
MA33299B1 (fr) | Nouvelle formulation de naproxène | |
MX2011013032A (es) | Inhibidores de fosfatidilinositol 3-cinasa. | |
MA37666B1 (fr) | Sel de camsylate | |
UA104988C2 (uk) | Похідні піроніндолу та спосіб їх отримання | |
PL1888514T3 (pl) | Sole podstawionych estrów kwasu alofanowego i ich zastosowanie w środkach leczniczych |